Literature DB >> 2162939

Oestrogen receptor staining of paraffin-embedded breast carcinomas following short fixation in formalin: a comparison with cytosolic and frozen section receptor analyses.

W A Raymond1, A S Leong.   

Abstract

This paper describes an improved immunohistochemical method for demonstrating oestrogen receptor (OR) protein in paraffin-embedded sections of tissue fixed for 1.5 h in formalin. Thirty-two cases of infiltrating ductal breast carcinoma were stained with a monoclonal anti-OR antibody (H222), using a standard streptavidin-biotin method, following pretreatment with pronase. OR counts in paraffin sections were compared with those of frozen sections and with cytosolic values determined by a dextran-coated charcoal method. Twenty-seven of the carcinomas were OR-positive in paraffin sections. There was concordance between the paraffin section and the frozen section-determined receptor status in 30 cases (94 per cent) and a strong correlation was observed (r = 0.76; P less than 0.0001). Similarly, OR counts in paraffin sections correlated with cytosolic OR values (r = 0.60; P less than 0.001) and there was concordance in 97 per cent of cases. The percentage of positively-stained tumour cells in paraffin sections ranged from 0 to 94 per cent with staining intensities comparable to those seen in frozen sections. Staining of paraffin sections identified more OR-positive tumours than either frozen section staining or cytosolic assay. This study validates immunohistochemical OR analysis in formalin-fixed, paraffin-embedded breast carcinomas using a commercial anti-OR antibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162939     DOI: 10.1002/path.1711600405

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Tissue preparation for immunocytochemistry.

Authors:  J H Williams; B L Mepham; D H Wright
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

2.  Automation of immunohistochemical evaluation in breast cancer using image analysis.

Authors:  Keerthana Prasad; Avani Tiwari; Sandhya Ilanthodi; Gopalakrishna Prabhu; Muktha Pai
Journal:  World J Clin Oncol       Date:  2011-04-10

3.  A comparative study of cell proliferation markers in breast carcinomas.

Authors:  A S Leong; S Vinyuvat; C Suthipintawong; J Milios
Journal:  Clin Mol Pathol       Date:  1995-04

4.  Oestrogen and progesterone receptor expression in mammary fibromatosis.

Authors:  S A Rasbridge; C E Gillett; R R Millis
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

5.  Progestin receptors in meningiomas. Comparison of cytosolic assays with immunocytochemical identification in cryostat and paraffin sections.

Authors:  G Blaauw; J Koudstaal; M A Blankenstein; M Debets-Te Baerts; A H Gijzen
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

6.  Datamining approach for automation of diagnosis of breast cancer in immunohistochemically stained tissue microarray images.

Authors:  Keerthana Prasad; Bernhard Zimmermann; Gopalakrishna Prabhu; Muktha Pai
Journal:  Open Med Inform J       Date:  2010-05-28

7.  Storage Conditions and Immunoreactivity of Breast Cancer Subtyping Markers in Tissue Microarray Sections.

Authors:  Angela R Omilian; Gary R Zirpoli; Ting-Yuan David Cheng; Song Yao; Leighton Stein; Warren Davis; Karen L Head; Priya Nair; Thaer Khoury; Christine B Ambrosone; Wiam Bshara
Journal:  Appl Immunohistochem Mol Morphol       Date:  2020-04

8.  Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

Authors:  D N Poller; D R Snead; E C Roberts; M Galea; J A Bell; A Gilmour; C W Elston; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Characterisation of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas.

Authors:  S Moriuchi; K Shimizu; Y Miyao; T Hayakawa
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.